| 2022-04 |
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials |
Journal for Immunotherapy of Cancer. 2022 Apr;10(4):Article number e004273. |
 |
| 2022-02-24 |
Semaphorin 6C suppresses proliferation of pancreatic cancer cells via inhibition of the AKT/GSK3/beta-catenin/cyclin D1 pathway |
International Journal of Molecular Sciences. 2022 Feb 24;23(5):Article number 2608. |
|
| 2022-02-16 |
Current status of the spectrum and therapeutics of helicobacter pylori-negative mucosa-associated lymphoid tissue lymphoma |
Cancers. 2022 Feb 16;14(4):Article number 1005. |
|
| 2022-02-15 |
Semaphorin 4C promotes motility and immunosuppressive activity of cancer cells via CRMP3 and PD-L1 |
American Journal of Cancer Research. 2022 Feb 15;12(2):713-728. |
|
| 2022-02 |
Incidence and survival variations of upper tract urothelial cancer in Taiwan (2001-2010) |
International Journal of Urology. 2022 Feb;29(2):121-127. |
|
| 2022-02 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr |
Lancet Oncology. 2022 Feb;23(2):234-247. |
|
| 2022-01 |
Comparing survival and subsequent treatment of first-line tyrosine kinase inhibitors in patients of advanced lung adenocarcinoma with epidermal growth factor receptor mutation |
Journal of the Formosan Medical Association. 2022 Jan;121(1 Pt 1):170-180. |
|
| 2022-01 |
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study |
Gastric Cancer. 2022 Jan;25(1):207-217. |
|
| 2021-11-30 |
Survival outcomes of management in metastatic gastric adenocarcinoma patients |
Scientific Reports. 2021 Nov 30;11:Article number 23142. |
|
| 2021-11-20 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study |
Therapeutic Advances in Medical Oncology. 2021 Nov 20;Article in Press. |
|
| 2021-11-12 |
The prognostic and predictive role of chromogranin a in gastroenteropancreatic neuroendocrine tumors - A single-center experience |
Frontiers in Oncology. 2021 Nov 12;11:Article number 741096. |
|
| 2021-10-30 |
Assessment of brain functional activity using a miniaturized head-mounted scanning photoacoustic imaging system in awake and freely moving rats |
Biosensors. 2021 Oct 30;11(11):Article number 429. |
|
| 2021-10 |
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: A randomised, double-blind, multicentre, phase 2 study |
Lancet Oncology. 2021 Oct;22(10):1468-1482. |
|
| 2021-09-10 |
Stromal galectin-1 promotes colorectal cancer cancer-initiating cell features and disease dissemination through SOX9 and Beta-catenin: Development of niche-based biomarkers |
Frontiers in Oncology. 2021 Sep 10;11:Article number 716055. |
|
| 2021-08-03 |
An adjustable dark-field acoustic-resolution photoacoustic imaging system with fiber bundle-based illumination |
Biosensors-Basel. 2021 Aug 3;11(8):Article number 262. |
|
| 2021-07-26 |
Cancer registry coding via hybrid neural symbolic systems in the cross-hospital setting |
IEEE Access. 2021 Jul 26;9:112081-112096. |
|
| 2021-07-23 |
AUY922 induces retinal toxicity through attenuating TRPM1 |
Journal of Biomedical Science. 2021 Jul 23;28:Article number 55. |
|
| 2021-07-15 |
How may ramucirumab help improve treatment outcome for patients with gastrointestinal cancers? |
Cancers. 2021 Jul 15;13(14):Article number 3536. |
|
| 2021-07-15 |
No association between alcohol consumption and pancreatic cancer even among individuals genetically susceptible to the carcinogenicity of alcohol |
Scientific Reports. 2021 Jul 15;11:Article number 14567. |
|
| 2021-07 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab |
Gastric Cancer. 2021 Jul;24(4):946-958. |
|
| 2021-06-22 |
A Novel Invadopodia-Specific Marker for Invasive and Pro-Metastatic Cancer Stem Cells [Erratum:Frontiers in Oncology. 2021 May 31;11:Article number 638311.] |
Frontiers in Oncology. 2021 Jun 22;11:Article number 718849. |
|
| 2021-06-12 |
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers |
Oncoimmunology. 2021 Jun 12;10(1):Article number 1943253. |
|
| 2021-06-07 |
In vivo assessment of hypoxia levels in pancreatic tumors using a dual-modality ultrasound/photoacoustic imaging system |
Micromachines. 2021 Jun 7;12(6):Article number 668. |
|
| 2021-05-31 |
A novel invadopodia-specific marker for invasive and pro-metastatic cancer stem cells |
Frontiers in Oncology. 2021 May 31;11:Article number 638311. |
|
| 2021-05 |
High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial |
Radiotherapy and Oncology. 2021 May;158:146-154. |
|
| 2021-04-28 |
Inhibition of Beta-catenin activity abolishes LKB1 loss-driven pancreatic cystadenoma in mice |
International Journal of Molecular Sciences. 2021 Apr 28;22(9):Article number 4649. |
|
| 2021-04-12 |
An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan |
Scientific Reports. 2021 Apr 12;11:Article number 7881. |
|
| 2021-04 |
Phase I dose-escalation study of SCB01A, a microtubule inhibitor with vascular disrupting activity, in patients with advanced solid tumors |
Oncologist. 2021 Apr;26(4):e567-e579. |
|
| 2021-03-01 |
Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors |
Scientific Reports. 2021 Mar 1;11:Article number 4834. |
|
| 2021-03 |
A phase II clinical trial on the combination therapy of PHY906 plus capecitabine in hepatocellular carcinoma |
Oncologist. 2021 Mar;26(3):e367-e373. |
|
| 2021-01-13 |
Development of possible next line of systemic therapies for gemcitabine-resistant biliary tract cancers: A perspective from clinical trials |
Biomolecules. 2021 Jan 13;11(1):Article number 97. |
|
| 2021-01 |
c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation |
Cancer Science. 2021 Jan;112(1):243-253. |
|
| 2021-01 |
Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1 |
Pancreatology. 2021 Jan 10;21(1):192-199. |
|
| 2020-12-29 |
Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan |
PLoS ONE. 2020 Dec 29;15(12):Article number e0244487. |
|
| 2020-11-13 |
The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: Real-world experience in a Taiwanese cohort [Erraturm: Scientific Reports. 2020 May 4;10:Article number 7420.] |
Scientific Reports. 2020 Nov 13;10:Article number 20199. |
|
| 2020-10 |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study |
Liver International. 2020 Oct;40(10):2535-2543. |
|
| 2020-07-01 |
A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue |
Haematologica. 2020 Jul 1;105(7):e349-e354. |
|
| 2020-07 |
JSCO/ESMO/ASCO/JSMO/TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions |
Annals of Oncology. 2020 Jul;31(7):861-872. |
|
| 2020-05-26 |
Validation of genome-wide association study-identified single nucleotide polymorphisms in a case-control study of pancreatic cancer from Taiwan |
Journal of Biomedical Science. 2020 May 26;27:Article number 69. |
|
| 2020-05-04 |
The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: Real-world experience in a Taiwanese cohort |
Scientific Reports. 2020 May 4;10:Article number 7420. |
|
| 2020-05 |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data |
Gastric Cancer. 2020 May;23(3):510-519. |
|
| 2020-05 |
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer |
Journal for ImmunoTherapy of Cancer. 2020 May;8(1):Article number e00056. |
|
| 2020-04 |
Management of early stage gastro-oesophageal cancers: Expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty |
Expert Review of Anticancer Therapy. 2020 Apr;20(4):305-324. |
|
| 2020-04 |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours |
British Journal of Cancer. 2020 Apr;122(9):1324-1332. |
|
| 2020-03 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: A TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO |
Annals of Oncology. 2020 Mar;31(3):334-351. |
|
| 2020-02 |
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study |
Cancer Science. 2020 Feb;111(2):513-527. |
|
| 2020-01 |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: A randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer |
Gastric Cancer. 2020 Jan;23(1):143-153. |
|
| 2020-01 |
Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer [Erraturm: Oncogene. 2016 May;35(12):1517-1528.] |
Oncogene. 2020 Jan;39(4):946-949. |
|
| 2020-01 |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma–TCOG T1211 study |
European Journal of Cancer. 2020 Jan;124:123-130. |
|
| 2020-01 |
Liposomal irinotecan + 5-FU/LV in metastatic pancreatic cancer: Subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal NAPOLI-1 trial |
Pancreas. 2020 Jan;49(1):62-75. |
|
